X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
X4 Pharmaceuticals to Participate in the Stifel 2024 Healthcare Conference
BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that management will participate in the Stifel 2024 Healthcare Conference, taking place in New York, NY on November 18-19, 2024.
波士顿，2024年11月14日(GLOBE NEWSWIRE) -- x4制药（纳斯达克：XFOR）是一家致力于改善罕见免疫系统疾病患者生活的公司，今天宣布管理层将参加2024年11月18-19日在纽约举行的Stifel 2024医疗保健会议。
| Stifel 2024 Healthcare Conference | |
| Date: | Monday, November 18, 2024 |
| Time: | 4:10PM ET |
| Format: | Fireside Chat |
| Location: | Lotte New York Palace, New York |
| Webcast Link | |
| 2024年史蒂夫尔医疗保健大会 | |
| 日期： | 2024年11月18日星期一 |
| 时间： | 东部时间 4:10 PM |
| 格式： | 炉边聊天 |
| 地点： | 纽约乐天宫，纽约 |
| 网络研讨会链接 | |
A link for this live webcast will also be accessible through the "events & presentations" page in the investors section of X4 Pharmaceuticals' website. After the conclusion of the conference, a webcast replay will be available through the same link.
在x4制药网站的投资者部分，"活动和演示"页面也将提供此次直播网络研讨会的链接。会议结束后，可以通过相同链接访问网络研讨会重播。
The Company will be available for one-on-one meetings during this conference. Interested investors should contact their Stifel representative to request meetings.
公司将在本次会议期间提供一对一的会议。有意向的投资者应联系他们的Stifel代表以请求会议。
About X4 Pharmaceuticals
X4 is delivering progress for patients by developing and commercializing innovative therapies for those with rare diseases of the immune system and significant unmet needs. Leveraging our expertise in CXCR4 and immune system biology, we have successfully developed mavorixafor, which has received U.S. approval as XOLREMDI (mavorixafor) capsules in its first indication. We are also evaluating the use of mavorixafor in additional potential indications. X4 corporate headquarters are in Boston, Massachusetts and our research center of excellence is in Vienna, Austria. For more information, please visit our website at .
关于x4制药
X4制药正在为罕见免疫系统疾病患者提供进展，并开发和推广创新治疗方案，以满足他们的重大未满足需求。利用我们在CXCR4和免疫系统生物学方面的专业知识，我们已成功开发了mavorixafor，并在其第一个适应症中获得了美国批准 - XOLREMDI（mavorixafor）胶囊。我们还在评估mavorixafor在其他潜在适应症中的使用。X4制药的总部位于美国马萨诸塞州波士顿，研究中心位于奥地利维也纳。欲了解更多信息，请访问我们的网站。
Company Contact:
José Juves
Head of Corporate & Patient Affairs
jose.juves@x4pharma.com
公司联系人：
Jose Juves
企业和患者事务负责人
jose.juves@x4pharma.com
Investor Contact:
Daniel Ferry
Managing Director, LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
投资者联系人：
Daniel Ferry
LifeSci Advisors董事总经理
daniel@lifesciadvisors.com
(617) 430-7576
Source: X4 Pharmaceuticals
资料来源：X4 Pharmaceuticals